Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein
Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. The spike protein of se...
Saved in:
| Published in | Microbiology spectrum Vol. 10; no. 1; p. e0267621 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
23.02.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus.
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency.
IMPORTANCE
Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. |
|---|---|
| AbstractList | The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency.
Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response.The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. ABSTRACT The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three S2 subunits. Infected and vaccinated individuals generate antibodies against spike, which can neutralize the virus. Most antibodies target the receptor-binding domain (RBD) and N-terminal domain (NTD) of S1; however, antibodies against other regions of spike have also been isolated. The interhost variability in domain specificity and relative neutralization efficacy of the antibodies is still poorly characterized. To this end, we tested serum and plasma samples collected from 85 coronavirus disease 2019 (COVID-19) convalescent subjects. Samples were analyzed using seven immunoassays that employ different domains, subunits, and oligomeric forms of spike to capture the antibodies. Samples were also tested for their neutralization of pseudovirus containing SARS-CoV-2 spike and of replication-competent SARS-CoV-2. While the total amount of anti-spike antibodies produced varied among convalescent subjects, we observed an unexpectedly fixed ratio of RBD- to NTD-targeting antibodies. The relative potency of the response (defined as the measured neutralization efficacy relative to the total level of spike-targeting antibodies) also exhibited limited variation between subjects and was not associated with the overall amount of antispike antibodies produced. These studies suggest that host-to-host variation in the polyclonal response elicited against SARS-CoV-2 spike in early pandemic subjects is primarily limited to the quantity of antibodies generated rather than their domain specificity or relative neutralization potency. IMPORTANCE Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus. Here, we show that the observed variation in the neutralizing activity of the antibody responses in COVID-19 convalescent subjects is caused by differences in the amounts of antibodies rather than their recognition properties or the potency of their antiviral activity. These findings suggest that COVID-19 vaccine strategies that focus on enhancing the overall level of the antibodies will likely elicit a more uniformly efficacious protective response. |
| Author | Pentella, Michael A. Boyt, Devlin Hu, Guiping Jackson, J. Brooks Rojas Chávez, Roberth A. Merrill, Anna E. Haim, Hillel Ruggio, Natalie Maury, Wendy Fili, Mohammad Han, Changze Gallagher, Tom Schwery, Nathan Brown, Grant D. Van Ert, Hanora A. Sevcik, Kristina Dempewolf, Spencer Bohan, Dana W. Rogers, Kai Qing, Enya Knudson, C. Michael |
| Author_xml | – sequence: 1 givenname: Hanora A. surname: Van Ert fullname: Van Ert, Hanora A. organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 2 givenname: Dana W. surname: Bohan fullname: Bohan, Dana W. organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 3 givenname: Kai surname: Rogers fullname: Rogers, Kai organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 4 givenname: Mohammad surname: Fili fullname: Fili, Mohammad organization: Department of Industrial and Manufacturing Systems Engineering, Iowa State University, Ames, Iowa, United States – sequence: 5 givenname: Roberth A. surname: Rojas Chávez fullname: Rojas Chávez, Roberth A. organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 6 givenname: Enya orcidid: 0000-0002-7455-3463 surname: Qing fullname: Qing, Enya organization: Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, United States – sequence: 7 givenname: Changze surname: Han fullname: Han, Changze organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 8 givenname: Spencer surname: Dempewolf fullname: Dempewolf, Spencer organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 9 givenname: Guiping surname: Hu fullname: Hu, Guiping organization: Department of Industrial and Manufacturing Systems Engineering, Iowa State University, Ames, Iowa, United States – sequence: 10 givenname: Nathan surname: Schwery fullname: Schwery, Nathan organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 11 givenname: Kristina surname: Sevcik fullname: Sevcik, Kristina organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 12 givenname: Natalie surname: Ruggio fullname: Ruggio, Natalie organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 13 givenname: Devlin surname: Boyt fullname: Boyt, Devlin organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 14 givenname: Michael A. surname: Pentella fullname: Pentella, Michael A. organization: State Hygienic Laboratory, The University of Iowa, Iowa City, Iowa, United States – sequence: 15 givenname: Tom orcidid: 0000-0002-8601-5961 surname: Gallagher fullname: Gallagher, Tom organization: Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, United States – sequence: 16 givenname: J. Brooks surname: Jackson fullname: Jackson, J. Brooks organization: Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States – sequence: 17 givenname: Anna E. surname: Merrill fullname: Merrill, Anna E. organization: Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States – sequence: 18 givenname: C. Michael surname: Knudson fullname: Knudson, C. Michael organization: Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States – sequence: 19 givenname: Grant D. surname: Brown fullname: Brown, Grant D. organization: Department of Biostatistics, School of Public Health, The University of Iowa, Iowa City, Iowa, United States – sequence: 20 givenname: Wendy surname: Maury fullname: Maury, Wendy organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States – sequence: 21 givenname: Hillel orcidid: 0000-0002-6071-5089 surname: Haim fullname: Haim, Hillel organization: Department of Microbiology and Immunology, The University of Iowa, Iowa City, Iowa, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35080430$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt9u0zAUxiM0xMbYA3CDfMlNiv_ETnKDVBUYlSqBVtit5TgnnUtiB9sp6rvwsJh2RRsSXB3L5_t-58j-nmdn1lnIspcEzwih1Zswgo5-GmaYilLklDzJLigRPMdFXZ49OJ9nVyFsMcaEYE45fZadM44rXDB8kf1cmcFEaNGt8kZF4yxqIP4AsGg9v1nnC3eb03xpuzQsqZa2NTvTTqoPyFj0zg0qlXVaxXRGm7hHyrboBvqE2gH67CJYvUeuQ_EO0NxG07h2nwRhdDYAUpvkD_HQXY_mG6Drfq_d6JPR2BfZ0y5Ngqv7epl9_fD-y-Jjvvp0vVzMV7niuIg5EM5qBh0oCkSwRutKqUaImnFWgK6bhheM4kaRmmnFsBCNhrJqBeOcYabYZbY8cluntnL0ZlB-L50y8nDh_EYqH43uQbY16SgmiqiCFxrXijasA05wJ7QqcZNYb4-scWoGaDXY6FX_CPq4Y82d3LidrMqakKpOgNf3AO--TxCiHEzQ0PfKgpuCpILSmleiLJN0dpSqMFC5dZO36ZkkwfJ3QuQpIfKQEElJMrx6uNyfrU55SILyKNDeheChk-lTD7FIu5r-v2jyl_ME_7fnF-pR4W4 |
| CitedBy_id | crossref_primary_10_3390_vaccines11071136 |
| Cites_doi | 10.1038/s41422-020-00446-w 10.1128/JVI.01749-19 10.1128/JCM.02257-20 10.1126/science.abg5268 10.1074/jbc.M109.085472 10.1371/journal.pone.0025858 10.1074/jbc.RA119.009481 10.1111/trf.16119 10.1093/jalm/jfaa195 10.1055/s-0041-1723938 10.1128/JCM.02005-20 10.1016/j.cell.2020.05.025 10.1016/j.lanwpc.2021.100276 10.1016/j.jmb.2010.08.033 10.1080/22221751.2021.2017757 10.1016/j.chom.2021.03.005 10.1126/science.abc6952 10.1016/j.chom.2020.06.021 10.1038/s42003-021-01649-6 10.3389/fimmu.2021.637651 10.1016/j.cell.2021.03.029 10.1093/infdis/jiaa659 10.1093/clinchem/hvaa211 10.3389/fmicb.2020.584251 10.1038/s41586-020-2456-9 10.1128/mBio.01991-20 10.1038/s41467-021-21968-w 10.1126/science.abb2507 10.1128/Spectrum.01131-21 10.1002/bit.26367 10.1016/j.molcel.2020.04.022 10.1016/j.jcv.2020.104512 10.1172/JCI142004 10.1016/j.cell.2020.02.058 10.1016/j.isci.2021.103272 10.1128/JVI.00966-21 10.1126/science.abc5902 10.1016/j.bbrc.2005.08.032 10.1016/j.immuni.2020.06.001 10.1016/j.isci.2021.103341 10.1016/j.cell.2020.02.052 10.1126/science.abc2241 10.1038/s41586-021-03412-7 10.1128/JVI.02765-12 10.1128/JVI.00174-17 10.1016/j.cell.2021.06.005 10.1111/trf.16101 10.1038/s41586-020-2571-7 10.1016/j.celrep.2021.109109 10.1021/acsinfecdis.0c00701 10.1016/j.cell.2021.02.037 10.1093/jalm/jfaa188 10.1038/s41591-020-0998-x 10.3389/fimmu.2021.647934 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Van Ert et al. Copyright © 2022 Van Ert et al. 2022 Van Ert et al. |
| Copyright_xml | – notice: Copyright © 2022 Van Ert et al. – notice: Copyright © 2022 Van Ert et al. 2022 Van Ert et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.02676-21 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | He, Biao |
| Editor_xml | – sequence: 1 givenname: Biao surname: He fullname: He, Biao |
| ExternalDocumentID | oai_doaj_org_article_d91f201a1a454c09a2b3fe510f6ca70b PMC8791189 02676-21 35080430 10_1128_spectrum_02676_21 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: T32 AI007511 – fundername: NIAID NIH HHS grantid: R21 AI144215 – fundername: NIAID NIH HHS grantid: T32 AI007485 – fundername: NIGMS NIH HHS grantid: T32 GM007337 – fundername: NIGMS NIH HHS grantid: T32 GM139776 – fundername: NIAID NIH HHS grantid: R01 AI134733 – fundername: NIAID NIH HHS grantid: T32 AI007343 – fundername: BLRD VA grantid: I01 BX000207 – fundername: HHS | National Institutes of Health (NIH) grantid: T32AI007511 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: T32GM007337 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: R01AI134733 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: R21AI144215 funderid: https://doi.org/10.13039/100000002 – fundername: ; grantid: T32AI007511 – fundername: ; grantid: R21AI144215 – fundername: ; grantid: T32GM007337 – fundername: ; grantid: R01AI134733 |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV AGVNZ ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF CGR CUY CVF ECM EIF NPM BXI EBS FF UCJ 7X8 5PM |
| ID | FETCH-LOGICAL-a504t-e15393efea2e163bcc8aab6693534ec9bb54320ba193ca3066bce78d6355303a3 |
| IEDL.DBID | DOA |
| ISSN | 2165-0497 |
| IngestDate | Wed Aug 27 01:16:45 EDT 2025 Thu Aug 21 18:24:35 EDT 2025 Thu Jul 10 23:58:11 EDT 2025 Thu Feb 24 01:46:18 EST 2022 Tue Jul 22 01:41:59 EDT 2025 Thu Apr 24 23:06:36 EDT 2025 Tue Jul 01 00:42:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 SARS-CoV-2 spike glycoprotein receptor-binding domain spike protein antibody neutralization convalescent-phase plasma neutralizing antibodies N-terminal domain immunoglobulins adaptive immunity immunoassay |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a504t-e15393efea2e163bcc8aab6693534ec9bb54320ba193ca3066bce78d6355303a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
| ORCID | 0000-0002-7455-3463 0000-0002-8601-5961 0000-0002-6071-5089 |
| OpenAccessLink | https://doaj.org/article/d91f201a1a454c09a2b3fe510f6ca70b |
| PMID | 35080430 |
| PQID | 2622958677 |
| PQPubID | 23479 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d91f201a1a454c09a2b3fe510f6ca70b pubmedcentral_primary_oai_pubmedcentral_nih_gov_8791189 proquest_miscellaneous_2622958677 asm2_journals_10_1128_spectrum_02676_21 pubmed_primary_35080430 crossref_citationtrail_10_1128_spectrum_02676_21 crossref_primary_10_1128_spectrum_02676_21 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-23 |
| PublicationDateYYYYMMDD | 2022-02-23 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Microbiol Spectr |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2022 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_50_2 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_52_2 Amanat F (e_1_3_3_26_2) 2021 e_1_3_3_40_2 e_1_3_3_5_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_44_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_51_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_45_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 Muecksch, F, Wise, H, Batchelor, B, Squires, M, Semple, E, Richardson, C, McGuire, J, Clearly, S, Furrie, E, Greig, N, Hay, G, Templeton, K, Lorenzi, JCC, Hatziioannou, T, Jenks, S, Bieniasz, PD (B34) 2021; 223 Zhou, D, Dejnirattisai, W, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, Paesen, GC, Lopez-Camacho, C, Slon-Campos, J, Hallis, B, Coombes, N, Bewley, K, Charlton, S, Walter, TS, Skelly, D, Lumley, SF, Dold, C, Levin, R, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, S, James, W, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR (B13) 2021; 184 Klein, SL, Pekosz, A, Park, HS, Ursin, RL, Shapiro, JR, Benner, SE, Littlefield, K, Kumar, S, Naik, HM, Betenbaugh, MJ, Shrestha, R, Wu, AA, Hughes, RM, Burgess, I, Caturegli, P, Laeyendecker, O, Quinn, TC, Sullivan, D, Shoham, S, Redd, AD, Bloch, EM, Casadevall, A, Tobian, AA (B31) 2020; 130 Johnson, J, Zhai, Y, Salimi, H, Espy, N, Eichelberger, N, DeLeon, O, O'Malley, Y, Courter, J, Smith, AB, Madani, N, Sodroski, J, Haim, H (B24) 2017; 91 Solastie, A, Virta, C, Haveri, A, Ekstrom, N, Kantele, A, Miettinen, S, Lempainen, J, Jalkanen, P, Kakkola, L, Dub, T, Julkunen, I, Melin, M (B32) 2021; 9 Tang, T, Jaimes, JA, Bidon, MK, Straus, MR, Daniel, S, Whittaker, GR (B6) 2021; 7 Patel, EU, Bloch, EM, Clarke, W, Hsieh, YH, Boon, D, Eby, Y, Fernandez, RE, Baker, OR, Keruly, M, Kirby, CS, Klock, E, Littlefield, K, Miller, J, Schmidt, HA, Sullivan, P, Piwowar-Manning, E, Shrestha, R, Redd, AD, Rothman, RE, Sullivan, D, Shoham, S, Casadevall, A, Quinn, TC, Pekosz, A, Tobian, AAR, Laeyendecker, O (B35) 2021; 59 Haim, H, Salas, I, Sodroski, J (B49) 2013; 87 Wu, Y, Wang, F, Shen, C, Peng, W, Li, D, Zhao, C, Li, Z, Li, S, Bi, Y, Yang, Y, Gong, Y, Xiao, H, Fan, Z, Tan, S, Wu, G, Tan, W, Lu, X, Fan, C, Wang, Q, Liu, Y, Zhang, C, Qi, J, Gao, GF, Gao, F, Liu, L (B8) 2020; 368 Walls, AC, Park, YJ, Tortorici, MA, Wall, A, McGuire, AT, Veesler, D (B2) 2020; 181 Niu, L, Wittrock, KN, Clabaugh, GC, Srivastava, V, Cho, MW (B39) 2021; 12 Seydoux, E, Homad, LJ, MacCamy, AJ, Parks, KR, Hurlburt, NK, Jennewein, MF, Akins, NR, Stuart, AB, Wan, YH, Feng, J, Whaley, RE, Singh, S, Boeckh, M, Cohen, KW, McElrath, MJ, Englund, JA, Chu, HY, Pancera, M, McGuire, AT, Stamatatos, L (B40) 2020; 53 Gniadek, TJ, Thiede, JM, Matchett, WE, Gress, AR, Pape, KA, Fiege, JK, Jenkins, MK, Menachery, VD, Langlois, RA, Bold, TD (B29) 2021; 61 Raska, M, Takahashi, K, Czernekova, L, Zachova, K, Hall, S, Moldoveanu, Z, Elliott, MC, Wilson, L, Brown, R, Jancova, D, Barnes, S, Vrbkova, J, Tomana, M, Smith, PD, Mestecky, J, Renfrow, MB, Novak, J (B51) 2010; 285 Kong, L, Sheppard, NC, Stewart-Jones, GBE, Robson, CL, Chen, H, Xu, X, Krashias, G, Bonomelli, C, Scanlan, CN, Kwong, PD, Jeffs, SA, Jones, IM, Sattentau, QJ (B50) 2010; 403 Zhang, L, Li, Q, Liang, Z, Li, T, Liu, S, Cui, Q, Nie, J, Wu, Q, Qu, X, Huang, W, Wang, Y (B44) 2022; 11 Wrapp, D, Wang, N, Corbett, KS, Goldsmith, JA, Hsieh, CL, Abiona, O, Graham, BS, McLellan, JS (B4) 2020; 367 Chi, X, Yan, R, Zhang, J, Zhang, G, Zhang, Y, Hao, M, Zhang, Z, Fan, P, Dong, Y, Yang, Y, Chen, Z, Guo, Y, Zhang, J, Li, Y, Song, X, Chen, Y, Xia, L, Fu, L, Hou, L, Xu, J, Yu, C, Li, J, Zhou, Q, Chen, W (B16) 2020; 369 Rychert, J, Couturier, MR, Elgort, M, Lozier, BK, La'ulu, S, Genzen, JR, Straseski, JA, Delgado, JC, Slev, PR (B48) 2021; 6 Shang, B, Wang, XY, Yuan, JW, Vabret, A, Wu, XD, Yang, RF, Tian, L, Ji, YY, Deubel, V, Sun, B (B1) 2005; 336 Amanat, F, Thapa, M, Lei, T, Ahmed, SMS, Adelsberg, DC, Carreno, JM, Strohmeier, S, Schmitz, AJ, Zafar, S, Zhou, JQ, Rijnink, W, Alshammary, H, Borcherding, N, Reiche, AG, Srivastava, K, Sordillo, EM, van Bakel, H, Turner, JS, Bajic, G, Simon, V, Ellebedy, AH, Krammer, F (B25) 2021 Case, JB, Rothlauf, PW, Chen, RE, Liu, Z, Zhao, H, Kim, AS, Bloyet, LM, Zeng, Q, Tahan, S, Droit, L, Ilagan, MXG, Tartell, MA, Amarasinghe, G, Henderson, JP, Miersch, S, Ustav, M, Sidhu, S, Virgin, HW, Wang, D, Ding, S, Corti, D, Theel, ES, Fremont, DH, Diamond, MS, Whelan, SPJ (B30) 2020; 28 Johnson, J, Flores, MG, Rosa, J, Han, C, Salvi, AM, DeMali, KA, Jagnow, JR, Sparks, A, Haim, H (B23) 2020; 94 Nguyen-Contant, P, Embong, AK, Kanagaiah, P, Chaves, FA, Yang, H, Branche, AR, Topham, DJ, Sangster, MY (B20) 2020; 11 Huang, C, Tan, Z, Zhao, K, Zou, W, Wang, H, Gao, H, Sun, S, Bu, D, Chai, W, Li, Y (B52) 2021; 24 Hoffmann, M, Kleine-Weber, H, Schroeder, S, Kruger, N, Herrler, T, Erichsen, S, Schiergens, TS, Herrler, G, Wu, NH, Nitsche, A, Muller, MA, Drosten, C, Pohlmann, S (B5) 2020; 181 Berger Rentsch, M, Zimmer, G (B33) 2011; 6 Cervera, L, Gonzalez-Dominguez, I, Segura, MM, Godia, F (B55) 2017; 114 Jungbauer, C, Weseslindtner, L, Weidner, L, Gansdorfer, S, Farcet, MR, Gschaider-Reichhart, E, Kreil, TR (B27) 2021; 61 Voss, WN, Hou, YJ, Johnson, NV, Delidakis, G, Kim, JE, Javanmardi, K, Horton, AP, Bartzoka, F, Paresi, CJ, Tanno, Y, Chou, CW, Abbasi, SA, Pickens, W, George, K, Boutz, DR, Towers, DM, McDaniel, JR, Billick, D, Goike, J, Rowe, L, Batra, D, Pohl, J, Lee, J, Gangappa, S, Sambhara, S, Gadush, M, Wang, N, Person, MD, Iverson, BL, Gollihar, JD, Dye, JM, Herbert, AS, Finkelstein, IJ, Baric, RS, McLellan, JS, Georgiou, G, Lavinder, JJ, Ippolito, GC (B38) 2021; 372 Zost, SJ, Gilchuk, P, Chen, RE, Case, JB, Reidy, JX, Trivette, A, Nargi, RS, Sutton, RE, Suryadevara, N, Chen, EC, Binshtein, E, Shrihari, S, Ostrowski, M, Chu, HY, Didier, JE, MacRenaris, KW, Jones, T, Day, S, Myers, L, Eun-Hyung Lee, F, Nguyen, DC, Sanz, I, Martinez, DR, Rothlauf, PW, Bloyet, LM, Whelan, SPJ, Baric, RS, Thackray, LB, Diamond, MS, Carnahan, RH, Crowe, JE (B14) 2020; 26 Tada, T, Zhou, H, Dcosta, BM, Samanovic, MI, Mulligan, MJ, Landau, NR (B42) 2021; 24 Brouwer, PJM, Caniels, TG, van der Straten, K, Snitselaar, JL, Aldon, Y, Bangaru, S, Torres, JL, Okba, NMA, Claireaux, M, Kerster, G, Bentlage, AEH, van Haaren, MM, Guerra, D, Burger, JA, Schermer, EE, Verheul, KD, van der Velde, N, van der Kooi, A, van Schooten, J, van Breemen, MJ, Bijl, TPL, Sliepen, K, Aartse, A, Derking, R, Bontjer, I, Kootstra, NA, Wiersinga, WJ, Vidarsson, G, Haagmans, BL, Ward, AB, de Bree, GJ, Sanders, RW, van Gils, MJ (B10) 2020; 369 Collier, DA, De Marco, A, Ferreira, I, Meng, B, Datir, RP, Walls, AC, Kemp, SA, Bassi, J, Pinto, D, Silacci-Fregni, C, Bianchi, S, Tortorici, MA, Bowen, J, Culap, K, Jaconi, S, Cameroni, E, Snell, G, Pizzuto, MS, Pellanda, AF, Garzoni, C, Riva, A, Collaboration, C-N, Elmer, A, Kingston, N, Graves, B, McCoy, LE, Smith, KGC, Bradley, JR, Temperton, N, Ceron-Gutierrez, L, Barcenas-Morales, G, Consortium, C-GU, Harvey, W, Virgin, HW, Lanzavecchia, A, Piccoli, L, Doffinger, R, Wills, M, Veesler, D, Corti, D, Gupta, RK (B41) 2021; 593 Chen, HY, Huang, C, Tian, L, Huang, X, Zhang, C, Llewellyn, GN, Rogers, GL, Andresen, K, O'Gorman, MRG, Chen, YW, Cannon, PM (B54) 2021; 95 Hoffmann, M, Kleine-Weber, H, Pohlmann, S (B3) 2020; 78 Wang, N, Sun, Y, Feng, R, Wang, Y, Guo, Y, Zhang, L, Deng, YQ, Wang, L, Cui, Z, Cao, L, Zhang, YJ, Li, W, Zhu, FC, Qin, CF, Wang, X (B18) 2021; 31 Grenache, DG, Ye, C, Bradfute, SB (B47) 2021; 6 Jaaskelainen, AJ, Kuivanen, S, Kekalainen, E, Ahava, MJ, Loginov, R, Kallio-Kokko, H, Vapalahti, O, Jarva, H, Kurkela, S, Lappalainen, M (B45) 2020; 129 Cao, Y, Su, B, Guo, X, Sun, W, Deng, Y, Bao, L, Zhu, Q, Zhang, X, Zheng, Y, Geng, C, Chai, X, He, R, Li, X, Lv, Q, Zhu, H, Deng, W, Xu, Y, Wang, Y, Qiao, L, Tan, Y, Song, L, Wang, G, Du, X, Gao, N, Liu, J, Xiao, J, Su, XD, Du, Z, Feng, Y, Qin, C, Qin, C, Jin, R, Xie, XS (B7) 2020; 182 Amanat, F, Thapa, M, Lei, T, Ahmed, SMS, Adelsberg, DC, Carreño, JM, Strohmeier, S, Schmitz, AJ, Zafar, S, Zhou, JQ, Rijnink, W, Alshammary, H, Borcherding, N, Reiche, AG, Srivastava, K, Sordillo, EM, van Bakel, H, Turner, JS, Bajic, G, Simon, V, Ellebedy, AH, Krammer, F, Ahmed, B, Altman, D, Amoako, A, Awawda, M, Beach, K, Bermúdez-González, C, Chernet, R, Eaker, L, Fabre, S, Ferreri, ED, Floda, D, Gleason, C, Kleiner, G, Jurczyszak, D, Matthews, J, Mendez, W, Mulder, LCF, Polanco, J, Russo, K, Salimbangon, A, Saksena, M, Shin, AS, Sominsky, L, Suthakaran, S, Wajnberg, A (B37) 2021; 184 Tang, MS, Case, JB, Franks, CE, Chen, RE, Anderson, NW, Henderson, JP, Diamond, MS, Gronowski, AM, Farnsworth, CW (B36) 2020; 66 Wang, B, Goh, YS, Fong, SW, Young, BE, Ngoh, EZX, Chavatte, JM, Salleh, SNM, Yeo, NK, Amrun, SN, Hor, PX, Loh, CY, Lee, CY, Chan, YH, Chang, ZW, Tay, MZ, Rouers, A, Torres-Ruesta, A, Carissimo, G, Soh, MK, Lee, RTC, Xu, Y, Pada, S, Lin, RTP, Leo, YS, Lye, DC, Maurer-Stroh, S, Ng, LFP, Renia, L, Wang, CI (B43) 2021; 15 Wang, C, van Haperen, R, Gutierrez-Alvarez, J, Li, W, Okba, NMA, Albulescu, I, Widjaja, I, van Dieren, B, Fernandez-Delgado, R, Sola, I, Hurdiss, DL, Daramola, O, Grosveld, F, van Kuppeveld, FJM, Haagmans, BL, Enjuanes, L, Drabek, D, Bosch, BJ (B53) 2021; 12 Luchsinger, LL, Ransegnola, B, Jin, D, Muecksch, F, Weisblum, Y, Bao, W, George, PJ, Rodriguez, M, Tricoche, N, Schmidt, F, Gao, C, Jawahar, S, Pal, M, Schnall, E, Zhang, H, Strauss, D, Yazdanbakhsh, K, Hillyer, CD, Bieniasz, PD, Hatziioannou, T (B46) 2020; 58 Suryadevara, N, Shrihari, S, Gilchuk, P, VanBlargan, LA, Binshtein, E, Zost, SJ, Nargi, RS, Sutton, RE, Winkler, ES, Chen, EC, Fouch, ME, Davidson, E, Doranz, BJ, Chen, RE, Shi, PY, Carnahan, RH, Thackray, LB, Diamond, MS, Crowe, JE (B17) 2021; 184 Zhou, X, Ma, F, Xie, J, Yuan, M, Li, Y, Shaabani, N, Zhao, F, Huang, D, Wu, NC, Lee, CD, Liu, H, Li, J, Chen, Z, Hong, Y, Liu, WH, Xiao, N, Burton, DR, Tu, H, Li, H, Chen, X, Teijaro, JR, Wilson, IA, Xiao, C, Huang, Z (B9) 2021; 35 Brochot, E, Demey, B, Touze, A, Belouzard, S, Dubuisson, J, Schmit, JL, Duverlie, G, Francois, C, Castelain, S, Helle, F (B28) 2020; 11 Shah, P, Canziani, GA, Carter, EP, Chaiken, I (B19) 2021; 12 Dogan, M, Kozhaya, L, Placek, L, Gunter, C, Yigit, M, Hardy, R, Plassmeyer, |
| References_xml | – ident: e_1_3_3_19_2 doi: 10.1038/s41422-020-00446-w – ident: e_1_3_3_24_2 doi: 10.1128/JVI.01749-19 – ident: e_1_3_3_36_2 doi: 10.1128/JCM.02257-20 – ident: e_1_3_3_39_2 doi: 10.1126/science.abg5268 – ident: e_1_3_3_52_2 doi: 10.1074/jbc.M109.085472 – ident: e_1_3_3_34_2 doi: 10.1371/journal.pone.0025858 – ident: e_1_3_3_23_2 doi: 10.1074/jbc.RA119.009481 – ident: e_1_3_3_28_2 doi: 10.1111/trf.16119 – ident: e_1_3_3_48_2 doi: 10.1093/jalm/jfaa195 – ident: e_1_3_3_22_2 doi: 10.1055/s-0041-1723938 – ident: e_1_3_3_47_2 doi: 10.1128/JCM.02005-20 – ident: e_1_3_3_8_2 doi: 10.1016/j.cell.2020.05.025 – ident: e_1_3_3_44_2 doi: 10.1016/j.lanwpc.2021.100276 – ident: e_1_3_3_51_2 doi: 10.1016/j.jmb.2010.08.033 – ident: e_1_3_3_45_2 doi: 10.1080/22221751.2021.2017757 – ident: e_1_3_3_12_2 doi: 10.1016/j.chom.2021.03.005 – ident: e_1_3_3_17_2 doi: 10.1126/science.abc6952 – ident: e_1_3_3_31_2 doi: 10.1016/j.chom.2020.06.021 – ident: e_1_3_3_16_2 doi: 10.1038/s42003-021-01649-6 – ident: e_1_3_3_20_2 doi: 10.3389/fimmu.2021.637651 – ident: e_1_3_3_18_2 doi: 10.1016/j.cell.2021.03.029 – ident: e_1_3_3_35_2 doi: 10.1093/infdis/jiaa659 – ident: e_1_3_3_37_2 doi: 10.1093/clinchem/hvaa211 – ident: e_1_3_3_29_2 doi: 10.3389/fmicb.2020.584251 – ident: e_1_3_3_13_2 doi: 10.1038/s41586-020-2456-9 – ident: e_1_3_3_21_2 doi: 10.1128/mBio.01991-20 – ident: e_1_3_3_54_2 doi: 10.1038/s41467-021-21968-w – ident: e_1_3_3_5_2 doi: 10.1126/science.abb2507 – ident: e_1_3_3_33_2 doi: 10.1128/Spectrum.01131-21 – ident: e_1_3_3_56_2 doi: 10.1002/bit.26367 – ident: e_1_3_3_4_2 doi: 10.1016/j.molcel.2020.04.022 – ident: e_1_3_3_46_2 doi: 10.1016/j.jcv.2020.104512 – ident: e_1_3_3_32_2 doi: 10.1172/JCI142004 – ident: e_1_3_3_3_2 doi: 10.1016/j.cell.2020.02.058 – ident: e_1_3_3_53_2 doi: 10.1016/j.isci.2021.103272 – ident: e_1_3_3_55_2 doi: 10.1128/JVI.00966-21 – ident: e_1_3_3_11_2 doi: 10.1126/science.abc5902 – ident: e_1_3_3_2_2 doi: 10.1016/j.bbrc.2005.08.032 – ident: e_1_3_3_41_2 doi: 10.1016/j.immuni.2020.06.001 – ident: e_1_3_3_43_2 doi: 10.1016/j.isci.2021.103341 – ident: e_1_3_3_6_2 doi: 10.1016/j.cell.2020.02.052 – ident: e_1_3_3_9_2 doi: 10.1126/science.abc2241 – year: 2021 ident: e_1_3_3_26_2 article-title: The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD publication-title: medRxiv – ident: e_1_3_3_42_2 doi: 10.1038/s41586-021-03412-7 – ident: e_1_3_3_50_2 doi: 10.1128/JVI.02765-12 – ident: e_1_3_3_25_2 doi: 10.1128/JVI.00174-17 – ident: e_1_3_3_38_2 doi: 10.1016/j.cell.2021.06.005 – ident: e_1_3_3_30_2 doi: 10.1111/trf.16101 – ident: e_1_3_3_27_2 doi: 10.1038/s41586-020-2571-7 – ident: e_1_3_3_10_2 doi: 10.1016/j.celrep.2021.109109 – ident: e_1_3_3_7_2 doi: 10.1021/acsinfecdis.0c00701 – ident: e_1_3_3_14_2 doi: 10.1016/j.cell.2021.02.037 – ident: e_1_3_3_49_2 doi: 10.1093/jalm/jfaa188 – ident: e_1_3_3_15_2 doi: 10.1038/s41591-020-0998-x – ident: e_1_3_3_40_2 doi: 10.3389/fimmu.2021.647934 – volume: 403 start-page: 131 year: 2010 end-page: 147 ident: B50 article-title: Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity publication-title: J Mol Biol doi: 10.1016/j.jmb.2010.08.033 – volume: 78 start-page: 779 year: 2020 end-page: 784.E775 ident: B3 article-title: A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells publication-title: Mol Cell doi: 10.1016/j.molcel.2020.04.022 – volume: 26 start-page: 1422 year: 2020 end-page: 1427 ident: B14 article-title: Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein publication-title: Nat Med doi: 10.1038/s41591-020-0998-x – volume: 223 start-page: 389 year: 2021 end-page: 398 ident: B34 article-title: Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients publication-title: J Infect Dis doi: 10.1093/infdis/jiaa659 – volume: 9 year: 2021 ident: B32 article-title: A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies publication-title: Microbiol Spectr doi: 10.1128/Spectrum.01131-21 – volume: 181 start-page: 281 year: 2020 end-page: 292.E286 ident: B2 article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 24 start-page: 103341 year: 2021 ident: B42 article-title: Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera publication-title: iScience doi: 10.1016/j.isci.2021.103341 – volume: 35 start-page: 109109 year: 2021 ident: B9 article-title: Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109109 – volume: 369 start-page: 650 year: 2020 end-page: 655 ident: B16 article-title: A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2 publication-title: Science doi: 10.1126/science.abc6952 – volume: 593 start-page: 136 year: 2021 end-page: 141 ident: B41 article-title: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies publication-title: Nature doi: 10.1038/s41586-021-03412-7 – volume: 184 start-page: 2316 year: 2021 end-page: 2331.E2315 ident: B17 article-title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein publication-title: Cell doi: 10.1016/j.cell.2021.03.029 – volume: 6 start-page: 491 year: 2021 end-page: 495 ident: B47 article-title: Correlation of SARS-CoV-2 neutralizing antibodies to an automated chemiluminescent serological immunoassay publication-title: J Appl Lab Med doi: 10.1093/jalm/jfaa195 – volume: 295 start-page: 348 year: 2020 end-page: 362 ident: B22 article-title: The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization publication-title: J Biol Chem doi: 10.1074/jbc.RA119.009481 – volume: 87 start-page: 1884 year: 2013 end-page: 1889 ident: B49 article-title: Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility publication-title: J Virol doi: 10.1128/JVI.02765-12 – volume: 58 year: 2020 ident: B46 article-title: Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients publication-title: J Clin Microbiol doi: 10.1128/JCM.02005-20 – volume: 6 year: 2011 ident: B33 article-title: A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon publication-title: PLoS One doi: 10.1371/journal.pone.0025858 – volume: 129 start-page: 104512 year: 2020 ident: B45 article-title: Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation publication-title: J Clin Virol doi: 10.1016/j.jcv.2020.104512 – volume: 184 start-page: 3936 year: 2021 end-page: 3948.E10 ident: B37 article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 publication-title: Cell doi: 10.1016/j.cell.2021.06.005 – volume: 368 start-page: 1274 year: 2020 end-page: 1278 ident: B8 article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 publication-title: Science doi: 10.1126/science.abc2241 – volume: 367 start-page: 1260 year: 2020 end-page: 1263 ident: B4 article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation publication-title: Science doi: 10.1126/science.abb2507 – volume: 11 year: 2020 ident: B20 article-title: S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit publication-title: mBio doi: 10.1128/mBio.01991-20 – volume: 372 start-page: 1108 year: 2021 end-page: 1112 ident: B38 article-title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes publication-title: Science doi: 10.1126/science.abg5268 – year: 2021 ident: B25 article-title: The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD publication-title: medRxiv – volume: 59 year: 2021 ident: B35 article-title: Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers publication-title: J Clin Microbiol doi: 10.1128/JCM.02257-20 – volume: 94 year: 2020 ident: B23 article-title: The high content of fructose in human semen competitively inhibits broad and potent antivirals that target high-mannose glycans publication-title: J Virol doi: 10.1128/JVI.01749-19 – volume: 584 start-page: 450 year: 2020 end-page: 456 ident: B26 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 130 start-page: 6141 year: 2020 end-page: 6150 ident: B31 article-title: Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population publication-title: J Clin Invest doi: 10.1172/JCI142004 – volume: 114 start-page: 2507 year: 2017 end-page: 2517 ident: B55 article-title: Intracellular characterization of Gag VLP production by transient transfection of HEK 293 cells publication-title: Biotechnol Bioeng doi: 10.1002/bit.26367 – volume: 31 start-page: 101 year: 2021 end-page: 103 ident: B18 article-title: Structure-based development of human antibody cocktails against SARS-CoV-2 publication-title: Cell Res doi: 10.1038/s41422-020-00446-w – volume: 12 start-page: 647934 year: 2021 ident: B39 article-title: A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain publication-title: Front Immunol doi: 10.3389/fimmu.2021.647934 – volume: 12 start-page: 1715 year: 2021 ident: B53 article-title: A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies publication-title: Nat Commun doi: 10.1038/s41467-021-21968-w – volume: 285 start-page: 20860 year: 2010 end-page: 20869 ident: B51 article-title: Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition publication-title: J Biol Chem doi: 10.1074/jbc.M109.085472 – volume: 91 year: 2017 ident: B24 article-title: Induction of a tier-1-like phenotype in diverse tier-2 isolates by agents that guide HIV-1 Env to perturbation-sensitive, nonnative states publication-title: J Virol doi: 10.1128/JVI.00174-17 – volume: 584 start-page: 437 year: 2020 end-page: 442 ident: B12 article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 28 start-page: 475 year: 2020 end-page: 485.E475 ident: B30 article-title: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.06.021 – volume: 181 start-page: 271 year: 2020 end-page: 280.E278 ident: B5 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 4 start-page: 129 year: 2021 ident: B15 article-title: SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus publication-title: Commun Biol doi: 10.1038/s42003-021-01649-6 – volume: 6 start-page: 614 year: 2021 end-page: 624 ident: B48 article-title: Evaluation of three SARS CoV-2 IgG antibody assays and correlation with neutralizing antibodies publication-title: J Appl Lab Med doi: 10.1093/jalm/jfaa188 – volume: 15 start-page: 100276 year: 2021 ident: B43 article-title: Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians publication-title: Lancet Reg Health West Pac doi: 10.1016/j.lanwpc.2021.100276 – volume: 61 start-page: 17 year: 2021 end-page: 23 ident: B29 article-title: SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease publication-title: Transfusion doi: 10.1111/trf.16101 – volume: 53 start-page: 98 year: 2020 end-page: 105.e105 ident: B40 article-title: Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation publication-title: Immunity doi: 10.1016/j.immuni.2020.06.001 – volume: 29 start-page: 819 year: 2021 end-page: 833.E817 ident: B11 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – volume: 11 start-page: 1 year: 2022 end-page: 5 ident: B44 article-title: The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.2017757 – volume: 184 start-page: 2348 year: 2021 end-page: 2361.E2346 ident: B13 article-title: Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera publication-title: Cell doi: 10.1016/j.cell.2021.02.037 – volume: 24 start-page: 103272 year: 2021 ident: B52 article-title: The effect of N-glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor publication-title: iScience doi: 10.1016/j.isci.2021.103272 – volume: 369 start-page: 643 year: 2020 end-page: 650 ident: B10 article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability publication-title: Science doi: 10.1126/science.abc5902 – volume: 95 year: 2021 ident: B54 article-title: Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation publication-title: J Virol doi: 10.1128/JVI.00966-21 – volume: 12 start-page: 637651 year: 2021 ident: B19 article-title: The case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic publication-title: Front Immunol doi: 10.3389/fimmu.2021.637651 – volume: 38 start-page: 614 year: 2021 end-page: 621 ident: B21 article-title: SARS-CoV-2 infection during pregnancy in a rural Midwest all-delivery cohort and associated maternal and neonatal outcomes publication-title: Am J Perinatol doi: 10.1055/s-0041-1723938 – volume: 61 start-page: 12 year: 2021 end-page: 16 ident: B27 article-title: Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations publication-title: Transfusion doi: 10.1111/trf.16119 – volume: 336 start-page: 110 year: 2005 end-page: 117 ident: B1 article-title: Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2005.08.032 – volume: 7 start-page: 264 year: 2021 end-page: 272 ident: B6 article-title: Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin publication-title: ACS Infect Dis doi: 10.1021/acsinfecdis.0c00701 – volume: 182 start-page: 73 year: 2020 end-page: 84.E16 ident: B7 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 66 start-page: 1538 year: 2020 end-page: 1547 ident: B36 article-title: Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays publication-title: Clin Chem doi: 10.1093/clinchem/hvaa211 – volume: 11 start-page: 584251 year: 2020 ident: B28 article-title: Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals publication-title: Front Microbiol doi: 10.3389/fmicb.2020.584251 |
| SSID | ssj0001105252 |
| Score | 2.2159593 |
| Snippet | Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The... The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1 and three... ABSTRACT The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is arranged as a trimer on the virus surface, composed of three S1... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0267621 |
| SubjectTerms | Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Antibody Formation antibody neutralization convalescent-phase plasma COVID-19 COVID-19 - blood COVID-19 - immunology COVID-19 - virology Enzyme-Linked Immunosorbent Assay Host-Microbial Interactions Humans immunoassay Neutralization Tests Protein Domains Research Article SARS-CoV-2 SARS-CoV-2 - chemistry SARS-CoV-2 - genetics SARS-CoV-2 - immunology Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology spike protein |
| SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ta9UwFA5jQ_CL-G51SgRBEDLbvLTpx-t0booveL1j30KSplrcbcfaCf0v_lhP0he9MoafCk1CSs45OU-ac56D0LMkscax3BGXMEE4z0piRC5IkelU2jguRCDS_vAxPVzxdyfiZAulUy7MuILtnm7X4SJ_tmwqX4bkw_OL9Z4vm5QSnz--I2jOwSB3FovVp_d__q4kvj4bHa8xLx0LezDMQTf8UaDtvwxr_hsy-ZcPOriJbozgES8Gad9CW66-ja4N5ST7O-jXmK2Ej-EAHFYcj2FYeLn4siT7zTGh5CiEX0GvozkXq8VVjV83aw2PUJDe00p0PdZ1gYdouZ8Of248vO5xU2IAjXhRd5Vpih46hChbh_U3GN92oXV5Vv1w-O1pb5vABFHVd9Hq4M3X_UMyVl8gWsS8A-EJljNXOk0dgDZjrdTapGnOBOPO5sYIzmhsNEBAq-HkkRrrMll4BAN-UbN7aLtuavcAYSd5aRMnJTPgDD3_TOJ57SyctYQzUkfouReFmoSvwsmESjUJTQWhKZpEKJ6kpexIYu5raZxeNeTFPORsYPC4qvMrrwJzR0--HV6AKqrRllWRJyXgJp1oLriNc00NKx1sbmVqdRabCD2dFEiBsfobGF275qJVNPXV0z2FYITuDwo1T8UAKnsCtghlG6q28S2bLXX1PRCCywxclswf_vcyPkLXqU_j8Kn5bBdtQ6N7DOCqM09GS_oNchwl3w priority: 102 providerName: American Society for Microbiology |
| Title | Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35080430 https://journals.asm.org/doi/10.1128/spectrum.02676-21 https://www.proquest.com/docview/2622958677 https://pubmed.ncbi.nlm.nih.gov/PMC8791189 https://doaj.org/article/d91f201a1a454c09a2b3fe510f6ca70b |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA-yIvgifltPjwiCINRrk6ZNH-vpeaf4gese9xaSND2Lt-1x7Qn9X_xjnUm7y67I-eJToUloyEwyv2lmfkPI8zi2xvHchS7mIkySrAqNyEVYZjqVNopK4Ym0P35KDxfJ-xNxslHqC2PCRnrgceH2yjyuwEjpWCcisVGumeGVA02qUquzyODpCzZvw5nyf1dirM_GpmtMOIP3fOLixeXyFZZcSkPkBp3pbsm27JGn7f8b1vwzZHLDBh3cJrcm8EiLcdJ3yDXX3CU3xnKSwz3ya8pWosfgAPsVp1MYFp0XX-fhfnscsvDIh19Br6N1LlZH64a-aZcaHr4gPdJK9APVTUnHaLmfjn5pEV4PtK0ogEZaNH1t2nKADj7K1lF9CuO73rfOz-sfjr47G2zrmSDq5j5ZHLz9tn8YTtUXQi2ipAfhCZ5zVznNHIA2Y63U2qRpzgVPnM2NEQlnkdEAAa0GzyM11mWyRAQDdlHzB2TWtI17RKiTSWVjJyU3YAyRfyZGXjsLvpZwRuqAvEBRqGn7dMp7JkyqldCUF5picUCilbSUnUjMsZbG2VVDXq6HnI8MHld1fo0qsO6I5Nv-BaikmlRS_UslA_JspUAKNivewOjGtZedYilWT0cKwYA8HBVq_SkOUBkJ2AKSbana1ly2W5r6uycElxmYLJk__h-T3yE3GWZ4YNY-f0JmsDzuKeCu3uyS60Wx-Pxh12-136lUMCg |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELbQJgRfEO-UVyMhISFlJHacOB_LYLTsBUTXad8s23Eg0CYT6ZD6X_ix3DluoWia-BQpOStR7i73XHz3HCEvksQaxwsXuYSLKE3zKjKiEFGZ60zaOC6FJ9I-PMpG0_TDqTgNVZXYC_MN5_LOuh3dzf0-Pjo2_ogO8wjla9-A-ON8voOjk7IIe8i3ce8QEq_t4XD6cf_PH5YEZ7SxsJV54Vr4DsON2EZM8tT9F-HNf8sm_4pDezfJjQAg6bDX-C1yxTW3ydV-pOTyDvkVOpboCSTB_q3TUIpFJ8PPk2i3PYlYNPYlWCA1XvdjdbRu6Nt2ruHgh9IjtcRiSXVT0r5i7qejn1qE2EvaVhSAIx02i9q05RIEfKWto_oLrO8W_urkrP7u6PvZ0raeDaJu7pLp3rvj3VEUJjBEWsTpAhQoeMFd5TRzANyMtVJrk2UFFzx1tjBGpJzFRgMMtBqyj8xYl8sSUQzERs3vka2mbdwDQp1MK5s4KbmBgIgcNAly21nIt4QzUg_IS1SFCi7UKZ-dMKlWSlNeaYolAxKvtKVsIDLHeRqzy5a8Wi8561k8LhN-gyawFkQCbn8C7FEFf1ZlkVSAnXSiU5HauNDM8MrBB67KrM5jMyDPVwakwGFxF0Y3rj3vFMtwgjrSCA7I_d6g1rfiAJeRhG1A8g1T23iWzStN_dWTgsscwpYsHv73a3xGro2ODw_Uwfho_xG5zrCtA1v1-WOyBYLuCYCthXkavOo33WkqQg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ti9QwEA6yh-IX8d36GkEQhJxt07Tpx3rneuvpebjucd9CkqZavG0X2xP6X_yxTtLs6spx-KnQTEjJTDJPmplnEHoRRVoZmhtiIspIkmQVUSxnpMxkynUYlswRaX88Sg8WyftTduqjKm0ujJ_Bbld2S3eRb1f2qqx8PUL-2iUg_jhf7trSSSmxOeQ77rJqgnaKYvHp8M8flsjWaIv9VeaFfWEfhnHiLZ_kqPsvwpv_hk3-5YemN9ENDyBxMWr8Frpimtvo6lhScriDfvmMJXwCh2A369iHYuF58XlO9toTEpOZC8ECqdkmH6vDdYP326WEhytKb6kl-gHLpsRjxNxPg49bC7EH3FYYgCMumr5WbTmAgIu0NVh-hf5d71rnq_q7we_OBt06Noi6uYsW07df9g6Ir8BAJAuTHhTIaE5NZWRsALgprbmUKk1zymhidK4US2gcKgkwUEs4faRKm4yXFsWAb5T0Hpo0bWMeIGx4UunIcE4VOETLQRNZbjsN5y1mFJcBemlVIdYGINzpJOZirTThlCbiKEDhWltCeyJzW0_j7LIurzZdViOLx2XCb6wJbAQtAbd7AeYo_HoWZR5VgJ1kJBOW6DCXsaKVgQ2uSrXMQhWg52sDErBg7S2MbEx73ok4tRXULY1ggO6PBrUZigJctiRsAcq2TG3rW7ZbmvqbIwXnGbgtnj_872l8hq4d70_Fh9nR4SN0PbZZHTZTnz5GE5AzTwBr9eqpX1S_AZPFKd4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Limited+Variation+between+SARS-CoV-2-Infected+Individuals+in+Domain+Specificity+and+Relative+Potency+of+the+Antibody+Response+against+the+Spike+Glycoprotein&rft.jtitle=Microbiology+spectrum&rft.au=Van+Ert%2C+Hanora+A&rft.au=Bohan%2C+Dana+W&rft.au=Rogers%2C+Kai&rft.au=Fili%2C+Mohammad&rft.date=2022-02-23&rft.eissn=2165-0497&rft.volume=10&rft.issue=1&rft.spage=e0267621&rft_id=info:doi/10.1128%2Fspectrum.02676-21&rft_id=info%3Apmid%2F35080430&rft.externalDocID=35080430 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |